Treatment of Oral Crohn's Disease with Infliximab

Crohn's disease (CD) is a chronic inflammatory condition that is able to affect any portion of the digestive tract from the mouth to the anus. Oral Crohn's disease (OCD) is a well-documented extra-intestinal manifestation of CD, first described in 1969 by Dudney and Todd (1). Numerous published case reports and series have documented this condition's inconsistent and often disappointing response to traditional CD treatment modalities. More recently, several case reports have documented success in the treatment of OCD with infliximab, a chimeric monoclonal antibody against tumor necrosis factor alpha (2-8) (TNF-alpha). Here we report a case of severe OCD successfully treated with infliximab.